Focus
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Focus 5:141-150, Spring 2007
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* CME: Take the course for this article:
Substance Abuse: Diagnosis and Treatment
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Dermatis, H.
* Articles by Galanter, M.
* Search for Related Content
PubMed
* Articles by Dermatis, H.
* Articles by Galanter, M.

CLINICAL SYNTHESIS

Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders

Helen Dermatis, Ph.D, and Marc Galanter, M.D.

Correspondence: Address Correspondence to: Dr. Helen Dermatis, New York University Medical Center, Department of Psychiatry-Division of Alcoholism and Drug Abuse, NBV20N28, 550 First Avenue, New York, NY 10016.

In this review, we highlight recent developments in the pharmacological treatment of alcohol and other substance use disorders and in programs designed for those with dual diagnosis disorders. The depot formulation of naltrexone, which recently received U.S. Food and Drug Administration approval, presents a more effective alternative to oral administration for alcohol dependence. Inconsistent support for the efficacy of acamprosate, however, underscores the need for more research concerning its optimal use. Recent testing of a depot naltrexone preparation for opioid-dependent patients shows promise for its clinical use. Buprenorphine represents a viable treatment option for opioid-dependent patients when combined with psychosocial modalities such as network therapy or contingency management. There has been an increase in the number of integrated programs for patients with a dual diagnosis, incorporating evidence-based psychosocial treatments combined with mutual self-help approaches, including 12-step-based and more global peer-led approaches.

CME Disclosure

Helen Dermatis, Ph.D., and Marc Galanter, M.D., Division of Alcoholism and Drug Abuse, New York University Medical Center, Department of Psychiatry, New York.

No relevant financial relationships to disclose.




This article has been cited by other articles:


Home page
APPI Online CMEHome page
Reference List for FOCUS Self-Assessment Examination
PsychiatryOnline CME, October 10, 2007; 2007(3): 2 - 2.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org